Review



fda-approved prestwick chemical library v2016  (Prestwick Chemical)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Prestwick Chemical fda-approved prestwick chemical library v2016
    (A) Flowchart describing the workflow used to identify compounds that inhibit IR-induced astrocyte reactivity in primary human astrocytes. (B) Jitter plot showing the results of the primary screens, represented as distance scores to the non-IR control for two primary human astrocyte batches and three compound libraries. The dashed line indicates the hit threshold. (C) Pie charts showing the frequency of hits across the three libraries and the distribution of therapeutic classes among hits from the FDA-approved <t>Prestwick</t> Chemicals library. (D) Schematic illustrating the origin of compounds and the experimental strategy used for the confirmation screening. (E) Jitter plot of confirmation screen results represented as distance score to the non-IR control across four primary human astrocyte batches. The dashed line represents the hit threshold. (F) Summary of confirmed hits categorized by compound origin, clinical testing, blood–brain barrier (BBB) permeability, therapeutic class, and molecular targets. The final 12 prioritized compounds are listed.
    Fda Approved Prestwick Chemical Library V2016, supplied by Prestwick Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fda-approved prestwick chemical library v2016/product/Prestwick Chemical
    Average 90 stars, based on 1 article reviews
    fda-approved prestwick chemical library v2016 - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Phenotypic Screening Identifies Flunarizine as an Inhibitor of Radiotherapy-Induced Astrocyte Reactivity with Therapeutic Potential in Glioblastoma"

    Article Title: Phenotypic Screening Identifies Flunarizine as an Inhibitor of Radiotherapy-Induced Astrocyte Reactivity with Therapeutic Potential in Glioblastoma

    Journal: bioRxiv

    doi: 10.1101/2025.07.12.664538

    (A) Flowchart describing the workflow used to identify compounds that inhibit IR-induced astrocyte reactivity in primary human astrocytes. (B) Jitter plot showing the results of the primary screens, represented as distance scores to the non-IR control for two primary human astrocyte batches and three compound libraries. The dashed line indicates the hit threshold. (C) Pie charts showing the frequency of hits across the three libraries and the distribution of therapeutic classes among hits from the FDA-approved Prestwick Chemicals library. (D) Schematic illustrating the origin of compounds and the experimental strategy used for the confirmation screening. (E) Jitter plot of confirmation screen results represented as distance score to the non-IR control across four primary human astrocyte batches. The dashed line represents the hit threshold. (F) Summary of confirmed hits categorized by compound origin, clinical testing, blood–brain barrier (BBB) permeability, therapeutic class, and molecular targets. The final 12 prioritized compounds are listed.
    Figure Legend Snippet: (A) Flowchart describing the workflow used to identify compounds that inhibit IR-induced astrocyte reactivity in primary human astrocytes. (B) Jitter plot showing the results of the primary screens, represented as distance scores to the non-IR control for two primary human astrocyte batches and three compound libraries. The dashed line indicates the hit threshold. (C) Pie charts showing the frequency of hits across the three libraries and the distribution of therapeutic classes among hits from the FDA-approved Prestwick Chemicals library. (D) Schematic illustrating the origin of compounds and the experimental strategy used for the confirmation screening. (E) Jitter plot of confirmation screen results represented as distance score to the non-IR control across four primary human astrocyte batches. The dashed line represents the hit threshold. (F) Summary of confirmed hits categorized by compound origin, clinical testing, blood–brain barrier (BBB) permeability, therapeutic class, and molecular targets. The final 12 prioritized compounds are listed.

    Techniques Used: Control, Permeability



    Similar Products

    fda-approved prestwick chemical library v2016  (Prestwick Chemical)
    90
    Prestwick Chemical fda-approved prestwick chemical library v2016
    (A) Flowchart describing the workflow used to identify compounds that inhibit IR-induced astrocyte reactivity in primary human astrocytes. (B) Jitter plot showing the results of the primary screens, represented as distance scores to the non-IR control for two primary human astrocyte batches and three compound libraries. The dashed line indicates the hit threshold. (C) Pie charts showing the frequency of hits across the three libraries and the distribution of therapeutic classes among hits from the FDA-approved <t>Prestwick</t> Chemicals library. (D) Schematic illustrating the origin of compounds and the experimental strategy used for the confirmation screening. (E) Jitter plot of confirmation screen results represented as distance score to the non-IR control across four primary human astrocyte batches. The dashed line represents the hit threshold. (F) Summary of confirmed hits categorized by compound origin, clinical testing, blood–brain barrier (BBB) permeability, therapeutic class, and molecular targets. The final 12 prioritized compounds are listed.
    Fda Approved Prestwick Chemical Library V2016, supplied by Prestwick Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fda-approved prestwick chemical library v2016/product/Prestwick Chemical
    Average 90 stars, based on 1 article reviews
    fda-approved prestwick chemical library v2016 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Flowchart describing the workflow used to identify compounds that inhibit IR-induced astrocyte reactivity in primary human astrocytes. (B) Jitter plot showing the results of the primary screens, represented as distance scores to the non-IR control for two primary human astrocyte batches and three compound libraries. The dashed line indicates the hit threshold. (C) Pie charts showing the frequency of hits across the three libraries and the distribution of therapeutic classes among hits from the FDA-approved Prestwick Chemicals library. (D) Schematic illustrating the origin of compounds and the experimental strategy used for the confirmation screening. (E) Jitter plot of confirmation screen results represented as distance score to the non-IR control across four primary human astrocyte batches. The dashed line represents the hit threshold. (F) Summary of confirmed hits categorized by compound origin, clinical testing, blood–brain barrier (BBB) permeability, therapeutic class, and molecular targets. The final 12 prioritized compounds are listed.

    Journal: bioRxiv

    Article Title: Phenotypic Screening Identifies Flunarizine as an Inhibitor of Radiotherapy-Induced Astrocyte Reactivity with Therapeutic Potential in Glioblastoma

    doi: 10.1101/2025.07.12.664538

    Figure Lengend Snippet: (A) Flowchart describing the workflow used to identify compounds that inhibit IR-induced astrocyte reactivity in primary human astrocytes. (B) Jitter plot showing the results of the primary screens, represented as distance scores to the non-IR control for two primary human astrocyte batches and three compound libraries. The dashed line indicates the hit threshold. (C) Pie charts showing the frequency of hits across the three libraries and the distribution of therapeutic classes among hits from the FDA-approved Prestwick Chemicals library. (D) Schematic illustrating the origin of compounds and the experimental strategy used for the confirmation screening. (E) Jitter plot of confirmation screen results represented as distance score to the non-IR control across four primary human astrocyte batches. The dashed line represents the hit threshold. (F) Summary of confirmed hits categorized by compound origin, clinical testing, blood–brain barrier (BBB) permeability, therapeutic class, and molecular targets. The final 12 prioritized compounds are listed.

    Article Snippet: On the second day, cells were treated with one of the following libraries: 176 compounds from Enzo SCREEN-WELL Protease, Kinase and Epigenetics (PKE) Inhibitor libraries, 330 compounds from the TargetMol Anti-Cancer drugs library (#L2110, v2018) or 1,280 compounds from the FDA-approved Prestwick Chemical library (prestwickchemical.com, v2016).

    Techniques: Control, Permeability